An AMCP Webinar, hosted by FormularyDecisions 

Please join us for an interactive session exploring artificial intelligence (AI)’s applications and limitations in the realm of evidence generation strategies. In this session, we will review insights from healthcare decision makers on AI adoption within their organizations. Additionally, our expert panelists will explore opportunities to mitigate concerns about AI acceptance and hesitation in today’s complex landscape. Using real-world case studies, we will also share how AI can be used to improve efficiencies in aggregating data and communicating evidence. 

Who should attend? Team members across the biopharma industry, managed care professionals, and other new and seasoned learners across healthcare can benefit from panelist insights and perspectives. Join us for an engaging discussion and unlock AI’s capabilities and potential in accelerating innovation! Register today to secure your spot!

 Learning Objectives: 

1. Review market research insights on AI adoption and perceptions among healthcare decision makers. 
2. Examine current capabilities and limitations of AI-powered tools. 
3. Identify best practices for the practical application of AI in health evidence generation strategy. 
4. Discuss trends and future opportunities to accelerate the trajectory of AI in an evolving landscape.

Unlock exclusive insights from the esteemed judges of the P&T Competition Finalist judges! Join us for this unique opportunity to learn directly from the experts who evaluate finalist submissions. 

Topics: 

• Monographs 
• PowerPoint Presentations 
• Live Presentations

A webinar sponsored by Sanofi.

1. Understand RSV Burden in US infants and review RSV epidemiology. 
2. Review the pivotal nirsevimab clinical development studies establishing safety and efficacy and supporting ACIP recommendations. 
3. Discuss global real-world data for nirsevimab efficacy, effectiveness and impact on RSV outcomes and nirsevimab safety. 
4. Implementing Optimal Immunization Strategies to Help Reduce RSV LRTI

This webinar is only offered to payers, formulary committees, or other similar entities responsible for selecting drugs for coverage or reimbursement. To join this webinar, you must be registered as a user of FormularyDecisions®.

A Science & Innovation Webinar, sponsored by GSK.

Lupus is a disease of progressive, and often irreversible, organ damage. It is more common in women and non-white populations. Factors such as long-term use of corticosteroids, high disease activity and flares may increase the risk of organ damage, while lupus nephritis may lead to significant chronic kidney disease, and potentially end stage kidney disease. Recently updated EULAR and KDIGO guidelines reflect up-to-date evidence and expert consensus and may be applied to your populations to improve patient outcomes, including minimizing toxicities, flares and risk of organ damage progression.

Neovascular, or wet, age-related macular degeneration (wet AMD) is a significant cause of central visual impairment, contributing to about half of all cases of blindness in Americans aged 50 years and older. The estimated number of individuals affected by wet AMD in the United States is projected to double to 5.4 million between 2010 and 2050. Although there is currently no cure for wet AMD, there are treatment options that slow disease progression.

In this webinar, key panelists will share insights curated from AMCP's Market Insights program on the patient burden of wet AMD and how payers can best manage it by considering factors such as timeliness of treatment, treatment durability, and cost-effective treatment strategies.

A Science & Innovation Webinar, sponsored by Abbvie.

Ulcerative colitis is a chronic, progressive, inflammatory bowel disease that damages the bowel over time and may result in decreased quality of life, hospitalizations, surgeries, and disability. The STRIDE II Recommendations for moderate to severe ulcerative colitis include long-term goals for the management of the disease.

There is a need for new treatment options, with a focus on long-term patient outcomes. An IL-23 inhibitor was recently approved for the treatment of moderate to severe ulcerative colitis. The objective of this webinar is to review the ulcerative colitis disease state, treatment guidelines, and the pivotal trials program for this recently approved indication for an IL-23 inhibitor.

A Science & Innovation Webinar, sponsored by Impact Education, LLC.

Retinal diseases result in remarkable morbidity among plan members, including vision loss and blindness. Furthermore, disparities exist in incidence and outcomes among those affected by social determinants of health (SDOH). This webcast, presented by ManagedCareEye.com, will educate managed care and payer professionals regarding best practices in enhancing retinal disease care equity and access.

Learning Objectives

• Identify current disparities in the care of retinal diseases.
• Outline the importance of anti-VEGF therapies with extended duration of effect for patients impacted by SDOH.
• Describe means by which to address the impact of SDOH via utilization management programs.